Targeted Next-generation Sequencing of Circulating Free DNA Enables Non-invasive Tumor Detection in Myxoid Liposarcomas

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2022 Feb 15

PMID 35164780

Authors

A E Eisenhardt

A Schmid

J Esser

Z Brugger

U Lausch

J Kiefer

M Braig

A Runkel

J Wehrle

R Claus

P Bronsert

A Leithner

B Liegl-Atzwanger

J Zeller

R Papini

M von Laffert

B M Pfitzner

G Koulaxouzidis

R E Giunta

S U Eisenhardt

David Braig

Affiliations

Soon will be listed here.

Citing Articles

Improved Quantification of Circulating Tumor DNA in Translocation-Associated Myxoid Liposarcoma by Simultaneous Detection of Breakpoints and Single Nucleotide Variants.

Schmid A, Lausch U, Runkel A, Kiefer J, Pauli T, Boerries M Cancer Med. 2025; 14(4):e70704.

PMID: 39980272 PMC: 11842865. DOI: 10.1002/cam4.70704.

Non-invasive monitoring of neoadjuvant radiation therapy response in soft tissue sarcomas by multiparametric MRI and quantification of circulating tumor DNA-A study protocol.

Runkel A, Braig D, Bogner B, Schmid A, Lausch U, Boneberg A PLoS One. 2023; 18(11):e0285580.

PMID: 37910565 PMC: 10619790. DOI: 10.1371/journal.pone.0285580.

Individualized Mini-Panel Sequencing of ctDNA Allows Tumor Monitoring in Complex Karyotype Sarcomas.

Braig D, Runkel A, Eisenhardt A, Schmid A, Zeller J, Pauli T Int J Mol Sci. 2022; 23(18).

PMID: 36142126 PMC: 9499617. DOI: 10.3390/ijms231810215.

Genotyping of Circulating Free DNA Enables Monitoring of Tumor Dynamics in Synovial Sarcomas.

Eisenhardt A, Brugger Z, Lausch U, Kiefer J, Zeller J, Runkel A Cancers (Basel). 2022; 14(9).

PMID: 35565213 PMC: 9105697. DOI: 10.3390/cancers14092078.

References

Durr H, Rauh J, Baur-Melnyk A, Knosel T, Lindner L, Roeder F . Myxoid liposarcoma: local relapse and metastatic pattern in 43 patients. BMC Cancer. 2018; 18(1):304. PMC: 5859402. DOI: 10.1186/s12885-018-4226-8. View

Movva S, Wen W, Chen W, Millis S, Gatalica Z, Reddy S . Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets. Oncotarget. 2015; 6(14):12234-47. PMC: 4494935. DOI: 10.18632/oncotarget.3498. View

Braig D, Becherer C, Bickert C, Braig M, Claus R, Eisenhardt A . Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas. Int J Cancer. 2019; 145(4):1148-1161. DOI: 10.1002/ijc.32216. View

Xiang H, Wang J, Hisaoka M, Zhu X . Characteristic sequence motifs located at the genomic breakpoints of the translocation t(12;16) and t(12;22) in myxoid liposarcoma. Pathology. 2008; 40(6):547-52. DOI: 10.1080/00313020802320424. View

Bratman S, Yang S, Iafolla M, Liu Z, Hansen A, Bedard P . Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2022; 1(9):873-881. DOI: 10.1038/s43018-020-0096-5. View

Koelsche C, Renner M, Hartmann W, Brandt R, Lehner B, Waldburger N . TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. J Exp Clin Cancer Res. 2014; 33:33. PMC: 4022359. DOI: 10.1186/1756-9966-33-33. View

Ventura Ferreira M, Crysandt M, Braunschweig T, Jost E, Voss B, Bouillon A . Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas. Int J Mol Sci. 2018; 19(2). PMC: 5855830. DOI: 10.3390/ijms19020608. View

Hofvander J, Viklund B, Isaksson A, Brosjo O, Vult von Steyern F, Rissler P . Different patterns of clonal evolution among different sarcoma subtypes followed for up to 25 years. Nat Commun. 2018; 9(1):3662. PMC: 6131146. DOI: 10.1038/s41467-018-06098-0. View

Unterrainer M, Ruzicka M, Fabritius M, Mittlmeier L, Winkelmann M, Rubenthaler J . PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. Eur Radiol Exp. 2020; 4(1):63. PMC: 7669926. DOI: 10.1186/s41747-020-00190-1. View

10.

Macconaill L, Burns R, Nag A, Coleman H, Slevin M, Giorda K . Unique, dual-indexed sequencing adapters with UMIs effectively eliminate index cross-talk and significantly improve sensitivity of massively parallel sequencing. BMC Genomics. 2018; 19(1):30. PMC: 5759201. DOI: 10.1186/s12864-017-4428-5. View

11.

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View

12.

de Vreeze R, de Jong D, Nederlof P, Ruijter H, Boerrigter L, Haas R . Multifocal myxoid liposarcoma--metastasis or second primary tumor?: a molecular biological analysis. J Mol Diagn. 2010; 12(2):238-43. PMC: 2871731. DOI: 10.2353/jmoldx.2010.090117. View

13.

Avanzini S, Kurtz D, Chabon J, Moding E, Hori S, Gambhir S . A mathematical model of ctDNA shedding predicts tumor detection size. Sci Adv. 2020; 6(50). PMC: 7732186. DOI: 10.1126/sciadv.abc4308. View

14.

Muratori F, Bettini L, Frenos F, Mondanelli N, Greto D, Livi L . Myxoid Liposarcoma: Prognostic Factors and Metastatic Pattern in a Series of 148 Patients Treated at a Single Institution. Int J Surg Oncol. 2018; 2018:8928706. PMC: 6011058. DOI: 10.1155/2018/8928706. View

15.

Joseph C, Hwang H, Jiao Y, Wood L, Kinde I, Wu J . Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas. Genes Chromosomes Cancer. 2013; 53(1):15-24. PMC: 4007004. DOI: 10.1002/gcc.22114. View